BIOMAT Database Logo BIOMAT Database Logo

Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation. 2022

Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Department of Radiation Oncology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan ryo108@kumamoto-u.ac.jp.

OBJECTIVE We retrospectively evaluated the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) with docetaxel, cisplatin, and 5-fluorouracil (TPF) for T3 N0 glottic carcinoma without vocal cord fixation. METHODS Twenty-five patients underwent TPF-CCRT without elective nodal irradiaion (ENI). After the RT of 40 Gy, five patients (20%) without tumor regression underwent surgery. Others underwent RT with a median total dose of 66 Gy. RESULTS Of the five patients who underwent surgery after the RT of 40 Gy, two showed residual carcinoma pathologically and the other three were confirmed to have complete pathological response to the treatment. The 5-year local control rate was 87%. No patients exhibited regional failure. No acute toxicities of grade 5 or late toxicities ≥grade 3 were observed. CONCLUSIONS TPF-CCRT provides excellent tumor control with acceptable toxicities. CCRT while omitting ENI is a reasonable approach for T3 N0 glottic carcinoma without vocal cord fixation.

UI MeSH Term Description Entries
D007822 Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. Cancer of Larynx,Laryngeal Cancer,Larynx Neoplasms,Cancer of the Larynx,Larynx Cancer,Neoplasms, Laryngeal,Cancer, Laryngeal,Cancer, Larynx,Cancers, Laryngeal,Cancers, Larynx,Laryngeal Cancers,Laryngeal Neoplasm,Larynx Cancers,Larynx Neoplasm,Neoplasm, Laryngeal,Neoplasm, Larynx,Neoplasms, Larynx
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
December 2015, Anticancer research,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-fluorouracil Improves Survival of Patients with Advanced Esophageal Cancer Compared with Conventional Concurrent Chemoradiotherapy with Cisplatin and 5-fluorouracil.
January 2018, Journal of Cancer,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
[Conservative surgery for glottic cancer with vocal cord fixation (T3)].
December 1999, Zhonghua er bi yan hou ke za zhi,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent chemoradiotherapy with docetaxel, cisplatin, and fluorouracil for patients with advanced external auditory canal squamous cell carcinoma: comparison with cisplatin-based concurrent chemoradiotherapy.
August 2025, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.
June 2012, Cancer chemotherapy and pharmacology,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer.
October 2022, Anticancer research,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma.
April 2014, International journal of urology : official journal of the Japanese Urological Association,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
May 2008, Acta oto-laryngologica,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
February 2016, Ear, nose, & throat journal,
Ryo Toya, and Takahiro Watakabe, and Daizo Murakami, and Tomohiko Matsuyama, and Tetsuo Saito, and Yoshiyuki Fukugawa, and Kohei Nishimoto, and Yorihisa Orita, and Natsuo Oya
Concurrent FP (5-fluorouracil, cisplatin) Chemoradiotherapy for Patients with Esophageal Cancer.
August 2003, Cancer research and treatment,
Copied contents to your clipboard!